Entheon Biomedical Corp. (OTC: ENTBF) a company dedicated to the application of the psychedelic DMT in the treatment of addiction, announced the launch of a psychedelics genetic test kit, through its wholly-owned subsidiary, HaluGen Life Sciences Inc.
The test will serve as a pre-screening platform for patients looking into psychedelics-assisted psychotherapy, giving out “genetic, personal and familial insights” to improve patient care and reduce possible risks associated with the therapy.
“For Entheon, …
Powered by WPeMatico